At BIO, executives point to signs the field can continue to advance
Adobe
Daniel covers the intersection of the health industry and the federal government. He reports on corporate influence in government, the health consequences of federal policies, and the politics of health care. Confidential tips can be sent on Signal at danielp.100.
SAN DIEGO — It is an unusual time to be in the vaccine business. But in the view of those gathered here at the BIO international conference this week, it’s not altogether a bleak one.
In fact, some vaccine makers are feeling more optimistic than they were a year ago — considering the circumstances, at least.
